🚀 Exciting news from Nura Bio! We’re growing our leadership team with two powerhouse additions: 👨⚕️ Dr. Lahar Mehta – our new Chief Medical Officer 💼 Scott Greenberg – our new Chief Business Officer With Lahar’s deep expertise in neurological clinical development and Scott’s strategic leadership across biotech, we’re gearing up for an exciting phase of growth! Their expertise will be pivotal as we advance our lead SARM1 inhibitor, NB-4746, and expand our neuroprotective pipeline. Welcome to the team, Lahar and Scott! Let’s keep pushing boundaries of therapeutic innovation for neurodegenerative disease. 💡 🧠 #Biotech #Neuroscience #NuraBio #SARM1 https://lnkd.in/e3hF6txs
Nura Bio
Biotechnology
South San Francisco, California 2,185 followers
We envision a world where the diagnosis of a neurological disorder comes with the hope of a cure.
About us
At Nura Bio (previously known as Proneurotech Inc.), we envision a world where the diagnosis of a neurological disorder comes with the hope of a cure. Expanding on recent breakthroughs in crucial neurodegenerative pathways, we are positioned to deliver transformative neuroprotective therapies to prevent and protect against neuronal loss and related neuroimmune dysregulation. Our research and development strategy is currently centered on two approaches: prevention of neuronal loss to preserve neurological function; and restoring the function of the neuron-glia axis to improve the nervous system’s immune surveillance capacity in response to neurological injury. Our discovery engine and emerging multi-target pipeline spans these approaches and is well positioned to address a broad range of neurological diseases. Nura Bio’s lead program is the SARM1 inhibitor program. SARM1, has recently emerged an axon-intrinsic metabolic sensor that is a pivotal driver of axonal degeneration and neuronal integrity. Axon degeneration is an early event in several neurological disorders, and halting it early has tremendous potential in the treatment of central, peripheral, and ocular neurological diseases.
- Website
-
http://www.nurabio.com
External link for Nura Bio
- Industry
- Biotechnology
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2018
- Specialties
- Axon Degeneration, Neurodegeneration, Neurobiology, Neurodegenerative Disease, Chemistry, and Neuroprotection
Locations
-
Primary
Get directions
161 Oyster Point Blvd
South San Francisco, California 94080, US
Employees at Nura Bio
Updates
-
As Nura Bio marches towards transformative neuroprotective therapies for patients, we'd like to pause for a moment to acknowledge the tremendous contributions of our team and the unwavering support of our investors and advisors. Together, we’re making crucial strides towards new treatments for neurological diseases. Learn more: https://bit.ly/4elui9S 🚀 Nura Bio has added $68M to the initial $73M series A raise in 2020, bringing the total raise to $140M+. This funding will advance a pipeline of neuroprotective therapies. 🧠 Brain-penetrant SARM1 inhibitor, NB-4746, completed a successful Phase 1 study in healthy volunteers. 🌟 Shilpa Sambashivan, Ph.D., CSO and founding team member, assumes reins as CEO, leading the team in translating groundbreaking research into potential therapies. #Biotech #Neuroscience #SARM1
-